Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) VP Brendan Luu sold 2,125 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $9.63, for a total value of $20,463.75. Following the sale, the vice president now directly owns 36,736 shares in the […]
Operator
Good afternoon, and welcome to Enanta Pharmaceuticals First Quarter 2021 Financial Results Conference Call. [Operator Instructions] There will be a question-and-answer session at the end of the prepared remarks. [Operator Instructions]
I would now like to turn the conference over to Jennifer Viera, Investor Relations. Please go ahead.
Jennifer Viera
Investor Relations
Thank you, operator, and thank you to everyone for joining us this afternoon. The news release with our fiscal first quarter financial results was issued this afternoon and is available on our website.
On the call today is Dr. Jay Luly, President and Chief Executive Officer; Paul Mellett, our Chief Financial Officer; and other members of Enanta s senior management team.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development
January 26, 2021 GMT
Brendan Luu, Senior Vice President, Business Development, Enanta Pharmaceuticals (Photo: Business Wire)
WATERTOWN, Mass. (BUSINESS WIRE) Jan 26, 2021
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures.